KR920702622A - 안구 발육의 치료 및 조절 - Google Patents

안구 발육의 치료 및 조절

Info

Publication number
KR920702622A
KR920702622A KR1019910701933A KR910701933A KR920702622A KR 920702622 A KR920702622 A KR 920702622A KR 1019910701933 A KR1019910701933 A KR 1019910701933A KR 910701933 A KR910701933 A KR 910701933A KR 920702622 A KR920702622 A KR 920702622A
Authority
KR
South Korea
Prior art keywords
eye
antagonist
choline
agonist
blocking
Prior art date
Application number
KR1019910701933A
Other languages
English (en)
Other versions
KR0147838B1 (ko
Inventor
앨런 엠. 래티스
리챠드 에이. 스톤
Original Assignee
원본미기재
더 트러스티스 오브 더 유니버시티 오브 펜실바니아
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 원본미기재, 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 filed Critical 원본미기재
Priority claimed from PCT/US1990/003444 external-priority patent/WO1990015604A1/en
Publication of KR920702622A publication Critical patent/KR920702622A/ko
Application granted granted Critical
Publication of KR0147838B1 publication Critical patent/KR0147838B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/695—Silicon compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

내용 없음

Description

안구 발육의 치료 및 조절
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (31)

  1. 뇌, 신경 조직 및(또는)신경절에는 효과적이지만, 눈의 전면에 있는 평활근에 대해서는 비교적 덜 선택적인 유효량의 무스카린 약제를 안구 투여하는 것으로 이루어진, 성장하는 동물의 눈의 비정상적 생후 성장 억제 방법.
  2. 뇌, 신경조직 및(또는)신경절의 세포들에서 M1콜린 작동성 수용체를 차단하는 데에 비교적 선택적이지만, 눈의 전면에 있는 평활근 세포에서 콜린 작동성 수용체를 차단하는 데에는 덜 선택적인 유효량의 무스카린 약리학적 길항약을 생후 성장하는 동안 눈에 투여하는 것으로 이루어진, 통상적으로 비정상적 성장을 초래하는 조건하에서 성장하는 동물의 눈의 비정상적 생후 축 성장 억제 방법.
  3. 제2항에 있어서, 길항약이 피렌제핀인 방법.
  4. 제 2항에 있어서, 길항약이 텔렌제핀인 방법.
  5. 제 2항에 있어서, 길항약이 o-메톡시-실라-핵소시클리움인 방법.
  6. 안구 투여용으로 적당한 pH로 완충된 담체 또는 희석체 중의 피렌제핀 유효량을 생후 성장하는 동안에 동물의 눈에 투여하는 것으로 이루어진, 통상적으로 비정상적인 성장을 초래하는 조건하게서 성장하는 동물의 눈의 비정상적 생후 축 성장 억제 방법.
  7. 뇌, 신경조직 및(또는)신경절의 세포들에서 M1콜린 작동성 수용체를 차단하는 데에는 비교적 선택적이지만, 눈의 전면에 있는 평활근 세포에서 콜린 작동성 수용체를 차단하는 데에는 덜 선택적이고, 안구 투여용으로 적당한 pH완충된 담체 또는 희석제 중에 존재하는 제약학적 유효량의 무스카린 약리학적 길항제로 이루어진, 성장하는 동물의 눈의 비정상적 생후 축 성장 억제를 위한 조성물.
  8. 제7항에 있어서, 길항약이 피렌제핀인 조성물.
  9. 제7항에 있어서, 길항약이 텔렌제핀인 조성물.
  10. 제7항에 있어서, 길항약이 o-메톡시-실라-핵소시클리움인 조성물.
  11. 유효량의 콜린 작동약을 성장하는 동물의 눈에 투여하는 것으로 이루어진, 성장하는 동물의 눈의 축 성장의 유도방법.
  12. 제11항에 있어서, 콜린 작동약이 카르바밀 콜린 클로라이드인 방법.
  13. 제11항에 있어서, 콜린 작동약이 필로카르핀인 방법.
  14. 제11항에 있어서, 콜린 작동약이 M1무스카린 길항약 McNeil-A-343인 방법.
  15. 유효량의 콜린 작동약을 성장하는 동물의 눈에 투여하는 것으로 이루어진, 축성 원시 발생을 억제하거나 제지하기 위한 성장하는 동물의 눈의 치료방법.
  16. 제15항에 있어서, 콜린 작동약이 카르바밀 콜린 클로라이드인 방법.
  17. 제 15항에 있어서, 콜린 작동약이 필로카르핀인 방법.
  18. 제15항에 있어서, 콜린 작동약이 M1무스카린 작동약 McNeil-A-343인 방법.
  19. 뇌, 신경조직 및(또는)신경절의 세포에서 M1콜린 작동성 수용체를 차단하는 데에는 비교적 선택적이지만, 눈의 전면에 있는 평활근에서 콜린 작동성 수용체를 차단하는 데에는 덜 선택적인 무스카린 약리학적 길항제 치료학적 유효량을 영장류 동물에게 투여하는 것으로 이루어진, 영장류 동물의 눈의 약시 발생 경감 및 억제방법.
  20. 뇌, 신경조직 및(또는)신경절의 세포에서 M1콜린 작동성 수용체를 차단하는 데에 비교적 선택적이지만, 눈의 전면에 있는 평활근의 세포에서 콜린 작동성 수용체를 차단하는 데에는 덜 선택적인 치료학적 유료량의 무스카린 약리학적 유료량의 무스카린 약리학적 길항약의, 통상적으로 비정상적 성장을 초래하는 조건하에서 성장하는 동물의 눈의 비정상적 생후 축 성장을 억제하기 위한 의약품 제조용 용도.
  21. 제 20항에 있어서, 길항약이 피렌제핀인 용도.
  22. 제20항에 있어서, 길항약이 텔렌제핀인 용도.
  23. 제20항에 있어서, 길항약이 o-메톡시-실라-핵소시클리움인 용도.
  24. 치료학적 유효량의 콜린 작동약의, 성장하는 동물의 눈의 축 성장을 유도하기 위한 의약 제조용 용도.
  25. 제24항에 있어서, 콜린 작동약이 카르바밀 콜린 클로라이드인 용도.
  26. 제24항에 있어서, 콜린 작동약이 필로카르핀인 용도.
  27. 제 24항에 있어서, 콜린 작동약이 M1무스카린 작동약 McNeil-A-343인 방법.
  28. 뇌, 신경조직 및(또는)신경절의 세포에서 M1콜린 작동성 수용체를 차단하는 데에는 비교적 선택적이지만, 눈의 전면에 있는 평활근 세포에서 콜린 작동성 수용체를 차단하는 데에는 덜 선택적인 치료학적 유효량의 무스카린 약리학적 길향약의, 영장동물의 눈의 약시 발생을 경감 및 약제하기 위한 의약 제조용 용도.
  29. 제28항에 있어서, 길항약이 피렌제핀인 용도.
  30. 제28항에 있어서, 길항약이 텔렌제핀인 용도.
  31. 제28항에 있어서, 길항약이 o-메톡시-실라-핵소시클리움인 용도.
    ※ 참고사항 : 최초출원 내용에 의하여 공개되는 것임.
KR1019910701933A 1989-06-21 1990-06-14 안구 발육의 치료 및 조절 KR0147838B1 (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US36929389A 1989-06-21 1989-06-21
US369,293 1989-06-21
US369293 1989-06-21
US07/522,241 US5122522A (en) 1989-06-21 1990-05-11 Treatment and control of ocular development
US522241 1990-05-11
US522,241 1990-05-11
PCT/US1990/003444 WO1990015604A1 (en) 1989-06-21 1990-06-14 Treatment and control of ocular development

Publications (2)

Publication Number Publication Date
KR920702622A true KR920702622A (ko) 1992-10-06
KR0147838B1 KR0147838B1 (ko) 1998-08-17

Family

ID=23454872

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019910701933A KR0147838B1 (ko) 1989-06-21 1990-06-14 안구 발육의 치료 및 조절

Country Status (3)

Country Link
US (1) US5122522A (ko)
EP (2) EP0737475B1 (ko)
KR (1) KR0147838B1 (ko)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1336490C (en) * 1988-06-03 1995-08-01 Paul Michael Iuvone Pharmacological treatment of ocular development
EP0478694B1 (en) * 1989-06-21 1997-01-15 The Trustees Of The University Of Pennsylvania use of pirenzepine, telenzepine oder O-methoxy -sila-hexocyclium in the manufacture of a medicament for the TREATMENT AND CONTROL OF OCULAR DEVELOPMENT
US5360801A (en) * 1989-06-21 1994-11-01 The Trustees Of The University Of Pennsylvania Pharmacological stimulation of eye growth
US5385939A (en) * 1993-04-30 1995-01-31 The Trustees Of The University Of Pennsylvania GABA-ergic modulation of eye growth
US5461052A (en) * 1993-04-30 1995-10-24 The Trustees Of The University Of Pennsylvania Prevention of myopia by tricyclic compounds
US5691323A (en) * 1995-05-12 1997-11-25 Merck & Co., Inc. Muscarine antagonists
US5574044A (en) * 1994-10-27 1996-11-12 Merck & Co., Inc. Muscarine antagonists
US5756508A (en) * 1995-10-31 1998-05-26 Merck & Co., Inc. Muscarine antagonists
AU5312198A (en) 1997-01-06 1998-08-03 Klaus Trier Aps Screening method
US6291466B1 (en) * 1998-07-30 2001-09-18 Allergan Sales, Inc. Cholinergic agents in the treatment of presbyopia
NZ529615A (en) * 2001-05-25 2005-07-29 Valley Forge Pharmaceuticals Pirenzepine ophthalmic gel
GB0324541D0 (en) * 2003-10-21 2003-11-26 Novartis Ag Organic compounds
GB0507298D0 (en) 2005-04-11 2005-05-18 Novartis Ag Organic compounds
US8372905B2 (en) 2010-08-31 2013-02-12 E I Du Pont De Nemours And Company Coating compositions containing low molecular weight polytrimethylene ether glycol
US8436081B2 (en) 2010-08-31 2013-05-07 U.S. Coatings IP Co. LLC. High film build coating composition containing low molecular weight polytrimethylene ether glycol
EP2638098A1 (en) 2010-11-10 2013-09-18 Coatings Foreign IP Co. LLC Radiation curable coating composition containing low molecular weight polytrimethylene ether glycol
EP2758047B1 (en) 2011-09-20 2018-12-19 Allergan, Inc. Compositions and methods for treating presbyopia, mild hyperopia, and irregular astigmatism
HRP20220762T1 (hr) 2018-04-24 2022-09-16 Allergan, Inc. Upotreba pilokarpin-hidroklorida u liječenju prezbiopije

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU188852B (en) * 1983-03-16 1986-05-28 Richter Gedeon Vegyeszeti Gyar Rt,Hu Process for producing thiazolidine derivatives active against gastric ulcer and intestinal ulcer
US5360801A (en) * 1989-06-21 1994-11-01 The Trustees Of The University Of Pennsylvania Pharmacological stimulation of eye growth
WO1993013777A1 (en) * 1992-01-21 1993-07-22 Merck & Co., Inc. Method of using m1-selective antimuscarinic pyridobenzodiazepinones in axial myopia therapy

Also Published As

Publication number Publication date
EP0629399B1 (en) 1999-08-11
EP0737475B1 (en) 2001-08-01
US5122522A (en) 1992-06-16
KR0147838B1 (ko) 1998-08-17
EP0629399A1 (en) 1994-12-21
EP0737475A3 (en) 1997-09-17
EP0737475A2 (en) 1996-10-16

Similar Documents

Publication Publication Date Title
KR920702622A (ko) 안구 발육의 치료 및 조절
AU754588B2 (en) Cholinergic agents in the treatment of presbyopia
DE69824730T2 (de) Zusammensetzungen, kits und verfahren zur hemmung von zerebralen neurovasculären störungen und muskulärem kopfschmerzen
EP0506658A1 (en) COMPOSITION AND METHOD FOR TREATING PAINFUL INFLAMMABLE OR ALLERGIC DISEASES.
AU647463B2 (en) A method and a pharmaceutical preparation for treating pain
US4490379A (en) Method of reducing intraocular pressure and treating glaucoma using corynanthine
JPH08511024A (ja) 眼内圧を低下させる方法および組成物
US5637604A (en) Treatment and control of ocular development
US3644647A (en) Treatment of glaucoma employing 5-(3-methylaminopropyl - 5h - dibenzo(a b) cycloheptene
AU617479B2 (en) Antiglaucoma compositions containing combinations of sympathomimetic agents and beta-1 selective beta-blockers
Bonomi et al. Ocular hypotensive action of labetalol in rabbit and human eyes
Leopold Trends in Ocular Therapy: The 23rd Sanford S. Gifford Memorial Lecture
Terner et al. Clinical experiences with demecarium bromide (BC-48) in the treatment of glaucoma
CA2369054C (en) Treatment and control of ocular development
Hoyng et al. Maintenance therapy of glaucoma patients with guanethidine (3%) and adrenaline (0.5%) once daily
Takahashi et al. Long-term treatment of various types of glaucoma with selected beta-adrenergic blocking agents.
SMITH MEDICAL TREATMENT OF SIMPLE (OPEN ANGLE) GLAUCOMA
NZ237398A (en) A synergistic combination of an analgesic and glucagon and its use in the treatment of colic pain

Legal Events

Date Code Title Description
A201 Request for examination
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20070511

Year of fee payment: 10

LAPS Lapse due to unpaid annual fee